BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 31715124)

  • 1. Hepatitis B viremia in HIV-coinfected individuals under antiretroviral therapy.
    Weissmann L; Picone CM; Gouvêa MSG; Ferreira PRA; Viana MSVB; Pinho JRR; Cassenote AJF; Segurado AC
    Braz J Infect Dis; 2019; 23(6):441-450. PubMed ID: 31715124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of HBeAg status and hepatitis B viraemia in HIV-infected patients with chronic hepatitis B in the HAART era in Brazil.
    Mendes-Correa MC; Pinho JR; Gomes-Gouvea MS; da Silva AC; Guastini CF; Martins LG; Leite AG; Silva MH; Gianini RJ; Uip DE
    BMC Infect Dis; 2011 Sep; 11():247. PubMed ID: 21933423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Lamivudine-Based Antiretroviral Treatment on Hepatitis B Viremia in HIV-Coinfected South Africans.
    Lukhwareni A; Gededzha MP; Amponsah-Dacosta E; Blackard JT; Burnett RJ; Selabe SG; Kyaw T; Mphahlele MJ
    Viruses; 2020 Jun; 12(6):. PubMed ID: 32545313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B Infection, Viral Load and Resistance in HIV-Infected Patients in Mozambique and Zambia.
    Wandeler G; Musukuma K; Zürcher S; Vinikoor MJ; Llenas-García J; Aly MM; Mulenga L; Chi BH; Ehmer J; Hobbins MA; Bolton-Moore C; Hoffmann CJ; Egger M;
    PLoS One; 2016; 11(3):e0152043. PubMed ID: 27032097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy.
    Lewin SR; Ribeiro RM; Avihingsanon A; Bowden S; Matthews G; Marks P; Locarnini SA; Ruxrungtham K; Perelson AS; Dore GJ
    Hepatology; 2009 Apr; 49(4):1113-21. PubMed ID: 19115219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy.
    Hafkin JS; Osborn MK; Localio AR; Amorosa VK; Kostman JR; Stern JJ; De La Torre P; Mounzer K; Frank I; Gross R; Chang KM; Lo Re V
    J Viral Hepat; 2014 Apr; 21(4):288-96. PubMed ID: 24597697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Antiretroviral Therapy on Liver Fibrosis Among Human Immunodeficiency Virus-Infected Adults With and Without HBV Coinfection in Zambia.
    Vinikoor MJ; Sinkala E; Chilengi R; Mulenga LB; Chi BH; Zyambo Z; Hoffmann CJ; Saag MS; Davies MA; Egger M; Wandeler G;
    Clin Infect Dis; 2017 May; 64(10):1343-1349. PubMed ID: 28158504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B virus drug resistance in HIV-1-infected patients taking lamivudine-containing antiretroviral therapy.
    Wongprasit P; Manosuthi W; Kiertiburanakul S; Sungkanuparph S
    AIDS Patient Care STDS; 2010 Apr; 24(4):205-9. PubMed ID: 20377434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HBV genotypes and drug resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected patients.
    Archampong TN; Boyce CL; Lartey M; Sagoe KW; Obo-Akwa A; Kenu E; Blackard JT; Kwara A
    Antivir Ther; 2017; 22(1):13-20. PubMed ID: 27167598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High incidence of lamivudine-resistance-associated vaccine-escape HBV mutants among HIV-coinfected patients on prolonged antiretroviral therapy.
    Pal A; Sarkar N; Saha D; Guha SK; Saha B; Chakrabarti S; Chakravarty R
    Antivir Ther; 2015; 20(5):545-54. PubMed ID: 25654813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proportion and factors associated with Hepatitis B viremia in antiretroviral treatment naïve and experienced HIV co-infected Ghanaian patients.
    Archampong TN; Lartey M; Sagoe KW; Obo-Akwa A; Kenu E; Gillani FS; Yang H; Boamah I; Flanigan T; Kwara A
    BMC Infect Dis; 2016 Jan; 16():14. PubMed ID: 26759172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HBV-DNA levels predict overall mortality in HIV/HBV coinfected individuals.
    Nikolopoulos GK; Paraskevis D; Psichogiou M; Hatzakis A
    J Med Virol; 2016 Mar; 88(3):466-73. PubMed ID: 26288334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher Mortality Despite Early Antiretroviral Therapy in Human Immunodeficiency Virus and Hepatitis B Virus (HBV)-Coinfected Patients With High HBV Replication.
    Kouamé GM; Boyd A; Moh R; Badje A; Gabillard D; Ouattara E; Ntakpe JB; Emième A; Maylin S; Chekaraou MA; Eholié SP; Zoulim F; Lacombe K; Anglaret X; Danel C;
    Clin Infect Dis; 2018 Jan; 66(1):112-120. PubMed ID: 29020361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity.
    Audsley J; Bent SJ; Littlejohn M; Avihingsanon A; Matthews G; Bowden S; Bayliss J; Luciani F; Yuen L; Fairley CK; Locarnini S; Lewin SR; Sasadeusz J
    AIDS; 2016 Jun; 30(10):1597-606. PubMed ID: 26950313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occult hepatitis B virus infection in a cohort of HIV-positive patients: correlation with hepatitis C virus coinfection, virological and immunological features.
    Morsica G; Ancarani F; Bagaglio S; Maracci M; Cicconi P; Cozzi Lepri A; Antonucci G; Bruno R; Santantonio T; Tacconi L; Baldelli F; Piscopo R; Santoro D; Lazzarin A; D'Arminio Monforte A;
    Infection; 2009 Oct; 37(5):445-9. PubMed ID: 19669092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B virus sub-genotype A1 infection is characterized by high replication levels and rapid emergence of drug resistance in HIV-positive adults receiving first-line antiretroviral therapy in Malawi.
    Aoudjane S; Chaponda M; González Del Castillo AA; O'Connor J; Noguera M; Beloukas A; Hopkins M; Khoo S; van Oosterhout JJ; Geretti AM
    Clin Infect Dis; 2014 Dec; 59(11):1618-26. PubMed ID: 25100867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria.
    Idoko J; Meloni S; Muazu M; Nimzing L; Badung B; Hawkins C; Sankalé JL; Ekong E; Murphy R; Kanki P; Thio CL
    Clin Infect Dis; 2009 Oct; 49(8):1268-73. PubMed ID: 19772386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lamivudine-resistant HBV infection in HIV-positive patients receiving antiretroviral therapy in a public routine clinic in Cameroon.
    Kouanfack C; Aghokeng AF; Mondain AM; Bourgeois A; Kenfack A; Mpoudi-Ngolé E; Ducos J; Delaporte E; Laurent C
    Antivir Ther; 2012; 17(2):321-6. PubMed ID: 22290198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals.
    Matthews GV; Seaberg E; Dore GJ; Bowden S; Lewin SR; Sasadeusz J; Marks P; Goodman Z; Philp FH; Tang Y; Locarnini S; Thio CL
    AIDS; 2009 Aug; 23(13):1707-15. PubMed ID: 19584701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications.
    Boyd A; Gozlan J; Maylin S; Delaugerre C; Peytavin G; Girard PM; Zoulim F; Lacombe K
    Hepatology; 2014 Aug; 60(2):497-507. PubMed ID: 24752996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.